Australia markets closed

Personalis, Inc. (04X.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
14.94+1.00 (+7.14%)
As of 02:30PM CET. Market open.
Full screen
Previous close17.25
Open14.18
Bid16.07 x N/A
Ask16.66 x N/A
Day's range13.94 - 14.94
52-week range0.86 - 14.94
Volume0
Avg. volume118
Market cap761.052M
Beta (5Y monthly)1.96
PE ratio (TTM)N/A
EPS (TTM)-2.08
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

    FREMONT, Calif., March 26, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay. NeXT Personal is designed to help detect minimal residual disease (MRD), monitor therapy response, and identify recurrence with high analytical sensitivity and accuracy, enhancing the decision-making process and ultimately improv

  • Business Wire

    Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FREMONT, Calif., March 19, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and March 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under Personalis’ 2020 Inducement Plan.

  • Business Wire

    Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

    FREMONT, Calif., February 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.